The FY2025 (Dec) proxy of AbCellera Biologics names 20 peer companies for pay. Among AbCellera Biologics and these peers, CEO pay was 8th highest of 9 and total shareholder return was the lowest of 9.
8th highest of 9in AbCellera Biologics and its pay peers, FY2025 (Dec) by CEO pay:
$5.4M$9.2M
9th highest of 9in AbCellera Biologics and its pay peers, FY2025 (Dec) by total shareholder return:
$9$291
Pay peer group, FY2025 (Dec) proxy
| Xenon Pharmaceuticals | ||
| Adaptive Biotechnologies | ||
| Structure Therapeutics | ||
| Vir Biotechnology | ||
| Arcutis Biotherapeutics | ||
| Spyre Therapeutics | ||
| Nurix Therapeutics | ||
| Agios Pharmaceuticals | ||
| Absci | Not disclosed | Not disclosed |
| Allogene Therapeutics | Not disclosed | Not disclosed |
| Entrada Therapeutics | Not disclosed | Not disclosed |
| Ligand Pharmaceuticals | Not disclosed | Not disclosed |
| Prime Medicine | Not disclosed | Not disclosed |
| Recursion Pharmaceuticals | Not disclosed | Not disclosed |
| Regenxbio | Not disclosed | Not disclosed |
| Relay Therapeutics | Not disclosed | Not disclosed |
| Sana Biotechnology | Not disclosed | Not disclosed |
| Verve Therapeutics | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
| Y-mAbs Therapeutics | Not disclosed | Not disclosed |
20 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.